Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia

Atherosclerosis

Volumn 185, Issue 2, 2006, Pages 307-312

  Van Tits, L J H ^a   Van Himbergen, T M ^b   Lemmers, H L M ^a   De Graaf, J ^a   Stalenhoef, A F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Apolipoprotein B; Atherosclerosis; C reactive protein; Carotid intima media thickness; Familial hypercholesterolemia; Oxidized low density lipoprotein; Statins

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; C-REACTIVE PROTEIN; CAROTID ARTERIES; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PYRROLES; SIMVASTATIN; TUNICA INTIMA; TUNICA MEDIA;

EID: 33644529999     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.06.006     Document Type: Article

References (29)

1. S. Ehara, M. Ueda, and T. Naruko Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes Circulation 103 15 2001 1955 1960
2. P. Holvoet, A. Mertens, and P. Verhamme Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease Arterioscler Thromb Vasc Biol 21 5 2001 844 848
3. P. Holvoet, T.B. Harris, and R.P. Tracy Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the health, aging, and body composition study Arterioscler Thromb Vasc Biol 23 8 2003 1444 1448
4. J. Hulthe, and B. Fagerberg Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study) Arterioscler Thromb Vasc Biol 22 7 2002 1162 1167
5. S. Toshima, A. Hasegawa, and M. Kurabayashi Circulating oxidized low-density lipoprotein levels. A biochemical risk marker for coronary heart disease Arterioscler Thromb Vasc Biol 20 10 2000 2243 2247
6. D. Steinberg, and A. Lewis Conner memorial lecture. Oxidative modification of LDL and atherogenesis Circulation 95 4 1997 1062 1071
7. L. Van Tits, J. de Graaf, and H. Hak-Lemmers Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis Lab Invest 83 1 2003 13 21
8. T. Vasankari, M. Ahotupa, and J. Toikka Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy Atherosclerosis 155 2 2001 403 412
9. A. Tamura, T. Watanabe, and M. Nasu Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients Circ J 67 10 2003 816 820
10. T.J. Smilde, S. Van Wissen, and H. Wollersheim Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial Lancet 357 9256 2001 577 581
11. T.J. Smilde, M.D. Trip, and H. Wollersheim Rationale, design, and baseline characteristics of a clinical trial comparing the effects of robust vs. conventional cholesterol lowering and intima-media thickness in patients with familial hypercholesterolemia. The atorvastatin vs. simvastatin on atherosclerosis progression (ASAP) study Clin Drug Invest 20 2 2000 67 79
12. S. Van Wissen, M.D. Trip, and T.J. Smilde Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy Atherosclerosis 165 2 2002 361 366
13. P.N. Demacker, M. Hessels, H. Toenhake-Dijkstra, and H. Baadenhuijsen Precipitation methods for high-density lipoprotein cholesterol measurement compared, and final evaluation under routine operating conditions of a method with a low sample-to-reagent ratio Clin Chem 43 4 1997 663 668
14. M.F. Lopes-Virella, G. Virella, and G. Evans Immunonephelometric assay of human apolipoprotein Al Clin Chem 26 8 1980 1205 1208
15. T.J. Smilde, H. Wollersheim, H. van Langen, and A.F. Stalenhoef Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness Clin Sci (Lond) 93 4 1997 317 324
16. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2 2004 227 239
17. R.L. Collins-Nakai, and G.R. Dagenais The role of the cardiovascular specialist in the prevention of cardiovascular diseases - executive summary Can J Cardiol 15 Suppl. G 1999 7G 16G
18. Van den Berkmortel F.W.P.J., H. Wollersheim, and H. Van Langen Two years of smoking cessation does not reduce arterial wall thickness and stiffness Neth J Med 62 7/8 2004 235 241
19. N. Rifai, and P.M. Ridker High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease Clin Chem 47 3 2001 403 411
20. Van Tits L.J.H., T.J. Smilde, and S. Van Wissen Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia J Invest Med 52 3 2004 177 184
21. P. Holvoet, D. Collen, and F. Van de Werf Malondialdehyde-modified LDL as a marker of acute coronary syndromes JAMA 281 18 1999 1718 1721
22. S. Tsimikas, C. Bergmark, and R.W. Beyer Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes J Am Coll Cardiol 41 3 2003 360 370
23. M.L. Liu, K. Ylitalo, and R. Salonen Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families Arterioscler Thromb Vasc Biol 24 8 2004 1492 1497
24. D. Steinberg Low density lipoprotein oxidation and its pathobiological significance J Biol Chem 272 34 1997 20963 20966
25. R. Bugiardini, O. Manfrini, and C. Pizzi Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms Circulation 109 21 2004 2518 2523
26. J.P. Halcox, W.H. Schenke, and G. Zalos Prognostic value of coronary vascular endothelial dysfunction Circulation 106 6 2002 653 658
27. M. Chen, T. Masaki, and T. Sawamura LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis Pharmacol Ther 95 1 2002 89 100
28. J.A. Berliner, and J.W. Heinecke The role of oxidized lipoproteins in atherogenesis Free Radic Biol Med 20 5 1996 707 727
29. P.M. Ridker, N. Rifai, and L. Rose Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 20 2002 1557 1565